PL2868315T3 - Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty - Google Patents

Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Info

Publication number
PL2868315T3
PL2868315T3 PL14188334T PL14188334T PL2868315T3 PL 2868315 T3 PL2868315 T3 PL 2868315T3 PL 14188334 T PL14188334 T PL 14188334T PL 14188334 T PL14188334 T PL 14188334T PL 2868315 T3 PL2868315 T3 PL 2868315T3
Authority
PL
Poland
Prior art keywords
lyophilates
lyophilization
methods
improved formulations
formulations
Prior art date
Application number
PL14188334T
Other languages
English (en)
Polish (pl)
Inventor
Martin Sven Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of PL2868315T3 publication Critical patent/PL2868315T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL14188334T 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty PL2868315T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99224107P 2007-12-04 2007-12-04
EP08857974.3A EP2224913B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby
EP14188334.8A EP2868315B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby

Publications (1)

Publication Number Publication Date
PL2868315T3 true PL2868315T3 (pl) 2018-06-29

Family

ID=40718143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14188334T PL2868315T3 (pl) 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Country Status (14)

Country Link
US (6) US8277845B2 (cg-RX-API-DMAC7.html)
EP (2) EP2224913B1 (cg-RX-API-DMAC7.html)
JP (5) JP5812318B2 (cg-RX-API-DMAC7.html)
CN (1) CN101932308B (cg-RX-API-DMAC7.html)
CA (3) CA3123813C (cg-RX-API-DMAC7.html)
CY (1) CY1119256T1 (cg-RX-API-DMAC7.html)
DK (1) DK2868315T3 (cg-RX-API-DMAC7.html)
ES (1) ES2638977T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171223T1 (cg-RX-API-DMAC7.html)
LT (1) LT2868315T (cg-RX-API-DMAC7.html)
PL (1) PL2868315T3 (cg-RX-API-DMAC7.html)
PT (1) PT2868315T (cg-RX-API-DMAC7.html)
SI (1) SI2868315T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009073711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2868315T1 (sl) 2007-12-04 2017-10-30 Biogen Chesapeake Llc Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
MX363473B (es) 2012-05-08 2019-03-25 Aeromics Inc Uso de fenilbenzamidas para tratar condiciones mediadas por acuaporina.
WO2013176772A1 (en) * 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
HK1224228A1 (zh) 2013-11-06 2017-08-18 Aeromics, Inc. 新型制剂
EP3113722A4 (en) * 2014-03-07 2017-12-06 Endologix, Inc. Forming hydrogels and materials therefor
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
EP3302514B1 (en) 2015-05-29 2022-07-06 University of Maryland, Baltimore Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
KR102681027B1 (ko) 2015-10-07 2024-07-02 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
US20170320862A1 (en) * 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
JP7165648B2 (ja) 2016-07-29 2022-11-04 バイオジェン チェサピーク エルエルシー Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法
CN108210501B (zh) 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
KR102336425B1 (ko) 2017-06-30 2021-12-07 무라다기카이가부시끼가이샤 반송 시스템 및 반송 방법
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法
US20220280537A1 (en) * 2021-03-04 2022-09-08 Biogen Chesapeake Llc Low-sorbing glyburide formulation and methods
WO2022195112A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating acneiform rash
CN113274361B (zh) * 2021-06-08 2022-05-06 吉林津升制药有限公司 一种烟酰胺冻干粉针剂及其制备方法
CN119173250A (zh) * 2022-03-03 2024-12-20 瑞迪制药有限公司 低吸附格列本脲试剂盒、制剂和方法
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB9003185D0 (en) * 1990-02-13 1990-04-11 Ici Plc Pharmaceutical compositions
WO1993013752A1 (en) 1992-01-21 1993-07-22 Sri International Improved process for preparing micronized polypeptide drugs
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5977109A (en) 1994-04-25 1999-11-02 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing compound DX-52-1 and lyophilized composition thereof
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
PL193447B1 (pl) * 1996-12-24 2007-02-28 Biogen Idec Inc Kompozycja interferonu, kompozycja farmaceutycznainterferonu oraz sposób stabilizowania kompozycjiinterferonu
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1999006024A1 (en) 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
EP1082132A1 (en) * 1998-05-29 2001-03-14 Biogen, Inc. Recombinant human interferon beta-1a (ifn-beta-1a) formulation
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
JP3956654B2 (ja) 2000-06-29 2007-08-08 小野薬品工業株式会社 Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002079778A2 (en) 2001-03-28 2002-10-10 Rheologics, Inc. In vivo delivery methods and compositions
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US20030125338A1 (en) 2001-06-12 2003-07-03 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
DK1408966T3 (da) * 2001-07-17 2008-06-16 N Gene Res Lab Inc Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
AU2003222020B2 (en) 2002-03-20 2008-08-28 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
NZ551128A (en) 2004-05-20 2010-03-26 Diamedica Inc Use of hepatic parasympathetic tone modulator and diabetes drug combinations for treating insulin resistance
JP5085326B2 (ja) 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
WO2006087232A1 (en) 2005-02-17 2006-08-24 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
US7659281B2 (en) 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
PL2071917T3 (pl) 2006-09-29 2013-04-30 Infa Sa System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
SI2868315T1 (sl) * 2007-12-04 2017-10-30 Biogen Chesapeake Llc Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to

Also Published As

Publication number Publication date
EP2868315A1 (en) 2015-05-06
JP2015134763A (ja) 2015-07-27
LT2868315T (lt) 2017-09-25
EP2868315B1 (en) 2017-05-31
US20150141516A1 (en) 2015-05-21
EP2224913A1 (en) 2010-09-08
US20210244669A1 (en) 2021-08-12
CA3240562A1 (en) 2009-06-11
SI2868315T1 (sl) 2017-10-30
JP5812318B2 (ja) 2015-11-11
CA2707484A1 (en) 2009-06-11
JP6377189B2 (ja) 2018-08-22
PT2868315T (pt) 2017-09-04
JP6603762B2 (ja) 2019-11-06
DK2868315T3 (en) 2017-09-04
US8858997B2 (en) 2014-10-14
US20100273886A1 (en) 2010-10-28
JP6866438B2 (ja) 2021-04-28
EP2224913A4 (en) 2013-04-24
EP2224913B1 (en) 2014-10-15
US20190099372A1 (en) 2019-04-04
WO2009073711A1 (en) 2009-06-11
JP6084639B2 (ja) 2017-02-22
ES2638977T3 (es) 2017-10-24
HRP20171223T1 (hr) 2017-11-03
CN101932308B (zh) 2014-11-05
JP2018197244A (ja) 2018-12-13
US10426729B2 (en) 2019-10-01
CN101932308A (zh) 2010-12-29
US8277845B2 (en) 2012-10-02
US10869835B2 (en) 2020-12-22
US10117834B2 (en) 2018-11-06
JP2020007334A (ja) 2020-01-16
JP2011505424A (ja) 2011-02-24
CA3123813A1 (en) 2009-06-11
CA3123813C (en) 2024-10-08
US20200093747A1 (en) 2020-03-26
CY1119256T1 (el) 2018-02-14
JP2017128569A (ja) 2017-07-27
US20130245069A1 (en) 2013-09-19
CA2707484C (en) 2021-08-10

Similar Documents

Publication Publication Date Title
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
ZA201203709B (en) Immunogenic compositions and methods
ZA200905621B (en) Solid preparation comprising alogliptin and pioglitazone
ZA200808485B (en) Lyophilized therapeutic peptibody formulations
PT2205336T (pt) Sistema e método para produzir formulações secas
IL197781A0 (en) Lyophilization methods and apparatuses
EP2111215A4 (en) MATERIALS AND METHOD FOR THE ADMINISTRATION OF ANTIOXIDANTS IN THE SKIN
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
IL211670A0 (en) Therapeutic protein formulations
EP2209750A4 (en) CEMENT FORMULATIONS AND PRODUCTS
EP2160183A4 (en) QUETIPIN EXTENDED FORMULATIONS WITH EXTENDED RELEASE AND METHOD OF MANUFACTURING THEREOF
GB0719202D0 (en) Compositions and methods for the skin and hair
PL2320739T3 (pl) Kompozycje farmaceutyczne i sposoby ich stabilizowania
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
PL2207567T3 (pl) Preparat immunogenny
EP2300018A4 (en) PAEONIFLORINE PREPARATIONS AND THEIR USE OF FAT REDUCTION
GB0719248D0 (en) Compounds and methods for pharmaceutical use
ZA201003524B (en) Injectable meclizine formulations and methods
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
ZA201008384B (en) Lasalocid compositions and methods
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0725007D0 (en) Carcino-immune therapeutic animal gland extract
GB0713093D0 (en) Pharmaceutical formulations
GB0715066D0 (en) Tobacco extraction methods and formulations